Russell R L, Donnelly J G, Palaszynski E W, Chan M M, Soldin S J
Department of Pharmacology, George Washington University, Washington, D.C.
Ther Drug Monit. 1991 Jan;13(1):32-6. doi: 10.1097/00007691-199101000-00003.
Thirty-five allograft recipients undergoing cyclosporine A (CsA) therapy were randomly selected to evaluate a "novel" in vitro assay that determines CsA and metabolite immunosuppressive activity in whole blood. The assay uses a third party mixed lymphocyte culture (MLC) system to which patient whole blood extracts containing CsA and metabolites are added. The ability of the extracted CsA and metabolites to inhibit proliferation in this system is proportional to the immune suppressive activity in whole blood. Comparison of the MLC suppression assay against Abbott TDx parent, TDx parent and metabolites, and radioreceptor assays utilizing cyclophilin or a 50-kDa binding protein isolated from JURKAT cytosol gave the following correlation coefficients: r = 0.612, r = 0.672, r = 0.362, and r = 0.775, respectively.
随机选择35名接受环孢素A（CsA）治疗的同种异体移植受者，以评估一种“新型”体外检测方法，该方法可测定全血中环孢素A及其代谢物的免疫抑制活性。该检测方法使用第三方混合淋巴细胞培养（MLC）系统，向其中添加含有环孢素A及其代谢物的患者全血提取物。提取的环孢素A及其代谢物在该系统中抑制增殖的能力与全血中的免疫抑制活性成正比。将MLC抑制检测与雅培TDx母体、TDx母体及其代谢物以及利用亲环蛋白或从JURKAT细胞质中分离出的50 kDa结合蛋白的放射受体检测进行比较，得到的相关系数分别为：r = 0.612、r = 0.672、r = 0.362和r = 0.775。
